{
    "nctId": "NCT05019365",
    "briefTitle": "Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy",
    "officialTitle": "Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, HER2-positive Breast Cancer, Cardiotoxicity",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Left Ventricular Systolic Dysfunction",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients with HER2 positive breast cancer who received anthracycline-containing chemotherapy followed by trastuzumab at least 5 years prior to enrolment;\n* age \\>18 years.\n\nExclusion Criteria:\n\n* standard contraindication to CMR (ex: pacemaker, metallic implant);\n* pregnancy;\n* eGFR \\<30 ml/min/1.73 m2) past medical history of heart failure or left ventricular systolic dysfunction.\n\nHealthy Volunteers:\n\nTwenty age and sex matched healthy volunteers will undergo a similar CMR protocol.\n\nInclusion Criteria:\n\n* least 18 years (they will be matched to the study participants)\n* no prior medical history (including cardiovascular health problems, medication or systemic illness)\n\nExclusion Criteria:\n\n* standard contraindication to CMR;\n* suspected pregnancy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}